Our findings corroborate the inhibition of oncogenic RTK signaling elicited by ganetespib in ErbB2+ breast cancer cells41, which further supports the multi-faceted anti-cancer potential of ganetespib. The gene discussed is ERBB2; the disease is breast cancer.